Authors : S Kalpana, S Kalpana, Sneha Priya Prabhakar, Sneha Priya Prabhakar, Ara Fauzia, Ara Fauzia
DOI : 10.18231/j.ijceo.2022.004
Volume : 8
Issue : 1
Year : 2022
Page No : 13-19
Aim: To study the response to the injection of intra-vitreal triamcinolone acetate (IVTA) in various indications and to identify the IOP rise between various groups.
Materials and Methods: An interventional, prospective study was conducted on 50 patients at vitreo-retinal department at tertiary eye hospital in Bangalore in the period of November 2015 to May 2017. Each patient was subjected to a detailed assessment which included patient’s demographic data & detailed history. Best corrected visual-acuity (BCVA), Intra ocular pressure(IOP) was recorded. Macular oedema is confirmed by optical coherence tomography and fluorescein angiography. Patients that received injection IVTA were followed up for 6 months.
Results: The mean age of subjects was 56.78±10.76 years, 54% were males and 46% were females. In the study, 46% of eyes were diagnosed at CSME, 38% as BRVO, 8% as pseudophakic CME, 6% as CRVO and 2% as Uveitis. The mean BCVA LogMAR at baseline was 0.87±0.43 and at 6 months follow up mean BCVA LogMAR was 0.59 ± 0.42. In the study mean IOP at baseline was 14.24±3.01 and at 6 months follow up mean IOP was 15.12 ± 3.60. There was significant increase in IOP at 1 month follow up. The mean central macular thickness (CMT) at baseline was 469.4±138.4 and at 6 months follow up mean CMT was 290.9 ± 140.7.
Conclusion: Although there is a risk of raised IOP, IVTA can be preferred as a modality of treating macular edema as it has good results and is very economical and affordable.
Keywords: IVTA, IOP, Macular oedema.